首页> 外文会议>PSB;Pacific symposium on biocomputing; 20090105-09;20090105-09; Kohala Coast, HI(US);Kohala Coast, HI(US) >IDENTIFICATION OF DISCRIMINATING BIOMARKERS FOR HUMAN DISEASE USING INTEGRATIVE NETWORK BIOLOGY
【24h】

IDENTIFICATION OF DISCRIMINATING BIOMARKERS FOR HUMAN DISEASE USING INTEGRATIVE NETWORK BIOLOGY

机译:利用集成网络生物学识别人类疾病的可区分生物标志物

获取原文
获取原文并翻译 | 示例

摘要

There is a strong clinical imperative to identify discerning molecular biomarkers of disease to inform diagnosis, prognosis, and treatment. Ideally, such biomarkers would be drawn from peripheral sources non-invasively to reduce costs and lower potential for complication. Advances in high-throughput genomics and proteomics have vastly increased the space of prospective molecular biomarkers. Consequently, the elucidation of molecular biomarkers of clinical importance often entails a genome- or proteome-wide search for candidates. Here we present a novel framework for the identification of disease-specific protein biomarkers through the integration of biofluid proteomes and inter-disease genomic relationships using a network paradigm. We created a blood plasma biomarker network by linking expression-based genomic profiles from 136 diseases to 1,028 detectable blood plasma proteins. We also created a urine biomarker network by linking genomic profiles from 127 diseases to 577 proteins detectable in urine. Through analysis of these molecular biomarker networks, we find that the majority (> 80%) of putative protein biomarkers are linked to multiple disease conditions. Thus, prospective disease-specific protein biomarkers are found in only a small subset of the biofluids proteomes. These findings illustrate the importance of considering shared molecular pathology across diseases when evaluating biomarker specificity. The proposed framework is amenable to integration with complimentary network models of biology, which could further constrain the biomarker candidate space, and establish a role for the understanding of multi-scale, inter-disease genomic relationships in biomarker discovery.
机译:鉴别疾病的分子生物学标志物以指导诊断,预后和治疗非常重要。理想地,这样的生物标志物将从非侵入性的外周来源中提取,以降低成本并降低并发症的可能性。高通量基因组学和蛋白质组学的进步极大地增加了预期分子生物标志物的空间。因此,阐明具有临床重要性的分子生物标志物通常需要在全基因组或蛋白质组范围内进行搜索。在这里,我们介绍了一种通过使用网络范式整合生物流体蛋白质组和疾病间基因组关系来鉴定疾病特异性蛋白质生物标志物的新颖框架。我们通过将136种疾病的基于表达的基因组概况与1,028种可检测的血浆蛋白相链接,创建了血浆生物标志物网络。我们还通过将127种疾病的基因组概况与尿液中可检测到的577种蛋白质联系起来,创建了尿液生物标志物网络。通过对这些分子生物标记物网络的分析,我们发现大多数(> 80%)推定的蛋白质生物标记物与多种疾病状况相关。因此,仅在一小部分生物流体蛋白质组中发现了前瞻性疾病特异性蛋白质生物标记。这些发现说明了在评估生物标志物特异性时,考虑跨疾病共享分子病理学的重要性。所提出的框架适于与生物学的互补网络模型整合,这可以进一步限制生物标志物候选空间,并在理解生物标志物发现中的多尺度,疾病间基因组关系方面发挥作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号